Guidelines for pharmacotherapy of Atrial fibrillation (JCS 2008)

Circulation Journal

Volumn 74, Issue 11, 2010, Pages 2479-2500

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; APRINDINE; BEPRIDIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRONCHODILATING AGENT; CIBENZOLINE; CILOSTAZOL; CLOPIDOGREL; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISOPYRAMIDE; FLECAINIDE; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PILSICAINIDE; PROPAFENONE; SOTALOL; THEOPHYLLINE; TICLOPIDINE; UNINDEXED DRUG; VERAPAMIL; VITAMIN K GROUP; WARFARIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ARTICLE; ARTIFICIAL HEART PACEMAKER; BLEEDING; CARDIOVASCULAR RISK; CARDIOVERSION; CATHETER ABLATION; CHRONIC RESPIRATORY TRACT DISEASE; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; DEEP VEIN THROMBOSIS; DISEASE CLASSIFICATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART MUSCLE POTENTIAL; HEART VALVE REPLACEMENT; HEART VENTRICLE FIBRILLATION; HUMAN; HYPERTENSION; HYPERTHYROIDISM; HYPERTROPHIC CARDIOMYOPATHY; INTERNATIONAL NORMALIZED RATIO; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PREVALENCE; RECURRENT DISEASE; REENTRY ARRHYTHMIA; SICK SINUS SYNDROME; SINUS RHYTHM; STUNNED HEART MUSCLE; THROMBOEMBOLISM; THROMBOSIS; TOOTH EXTRACTION; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; VALVULAR HEART DISEASE; WOLFF PARKINSON WHITE SYNDROME;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; HUMANS; JAPAN; PATIENT SELECTION; RISK ASSESSMENT; SOCIETIES, MEDICAL; TREATMENT OUTCOME;

EID: 78349242121     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-88-0001     Document Type: Article

References (174)

1. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406-412.
2. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. The Sicilian Gambit: A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation 1991; 84: 1831-1851.
3. The Antiarrhythmic Drugs Guideline Committee. The Guidelines for the use of antiarrhythmic drugs: Commentary on the CD-ROM version of the Guidelines and concept of the Sicilian Gambit. Tokyo: Lifemedicom Co., ltd. 2000 (in Japanese).
4. Guidelines for the Diagnosis and Treatment of Cardiovascular Diseases (1999-2000 JCS Joint Working Groups Report). Guidelines for Pharmacotherapy of Atrial Fibrillation. Jpn Circ J 2001; 65(Suppl V): 931-978 (in Japanese).
5. Fuster V, Rydén LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation). Circulation 2001; 104: 2118-2150.
6. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Circulation 2006; 114: 700-752.
7. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation: Analysis and implications. Arch Intern Med 1995; 155: 469-473.
8. Ohsawa M, Okayama A, Sakata K, Kato K, Itai K, Onoda T, et al. Rapid increase in estimated number of persons with atrial fibrillation in Japan: An analysis from national surveys on cardiovascular diseases in 1980, 1990 and 2000. J Epidemiol 2005; 15: 194-196.
9. Inoue H, Fujiki A, Origasa H, Ogawa S, Okumura K, Kubota I, et al. Prevalence of atrial fibrillation in the general population of Japan: An analysis based on periodic health examination. Int J Cardiol 2009; 137: 102-107.
10. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-2375.
11. The AFFIRM investigators. Baseline characteristics of patients with atrial fibrillation: The AFFIRM Study. Am Heart J 2002; 143: 991-1001.
12. Research Group for Antiarrhythmic Drug Therapy. Atrial fibrillation and thromboembolism: A multicenter cooperative study. J Cardiol 1998; 31: 227-238 (in Japanese).
13. Tomita F, Kohya T, Sakurai M, Kaji T, Yokoshiki H, Sato M, et al; for the Hokkaido Atrial Fibrillation Study Group. Prevalence and clinical characteristics of patients with atrial fibrillation. Analysis of 20,000 cases in Japan. Jpn Circ J 2000; 64: 653-658.
14. Lévy S, Maarek M, Coumel P, Guize L, Lekieffre J, Medvedowsky JL, et al. Characterization of different subsets of atrial fibrillation in general practice in France: The ALFA study. Circulation 1999; 99: 3028-3035.
15. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population- based cohort: The Framingham Heart Study. JAMA 1994; 271: 840-844.
16. Djoussé L, Levy D, Benjamin EJ, Blease SJ, Russ A, Larson MG, et al. Long-term alcohol consumption and the risk of atrial fibrillation in the Framingham Study. Am J Cardiol 2004; 93: 710-713.
17. Wang TJ, Parise H, Levy D, D'Agostino RB Sr, Wolf PA, Vasan RS, et al. Obesity and the risk of new-onset atrial fibrillation. JAMA 2004; 292: 2471-2477.
18. Fujishima M. Heart disease: Risk factor of cerebral vessel disease. The Journal of Board Certified Member of the Japanese Circulation Society 1998; 6: 19-26 (in Japanese).
19. Moe GK, Abildskov JA. Atrial fibrillation as a self-sustaining arrhythmia independent of focal discharge. Am Heart J 1959; 58: 59-70.
20. Packer DL, Bardy GH, Worley SJ, Smith MS, Cobb FR, Coleman RE, et al. Tachycardia-induced cardiomyopathy: A reversible form of left ventricular dysfunction. Am J Cardiol 1986; 57: 563-570.
21. Jaïs P, Haïssaguerre M, Shah DC, Chouairi S, Gencel L, Hocini M, et al. A focal source of atrial fibrillation treated by discrete radiofrequency ablation. Circulation 1997; 95: 572-576.
22. Haïssaguerre M, Jaïs P, Shah DC, Takahashi A, Hocini M, Quiniou G, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998; 339: 659-666.
23. Chen SA, Tai CT, Yu WC, Chen YJ, Tsai CF, Hsieh MH, et al. Right atrial focal atrial fibrillation: Electrophysiologic characteristics and radiofrequency catheter ablation. J Cardiovasc Electrophysiol 1999; 10: 328-335.
24. Hsu LF, Jaïs P, Keane D, Wharton JM, Deisenhofer I, Hocini M, et al. Atrial fibrillation originating from persistent left superior vena cava. Circulation 2004; 109: 828-832.
25. Shah D, Haïssaguerre M, Jaïs P, Hocini M. Nonpulmonary vein foci: Do they exist? Pacing Clin Electrophysiol 2003; 26: 1631-1635.
26. Kumagai K, Ogawa M, Noguchi H, Yasuda T, Nakashima H, Saku K. Electrophysiologic properties of pulmonary veins assessed using a multielectrode basket catheter. J Am Coll Cardiol 2004; 43: 2281-2289.
27. Pappone C, Rosanio S, Oreto G, Tocchi M, Gugliotta F, Vicedomini G, et al. Circumferential radiofrequency ablation of pulmonary vein ostia: A new anatomic approach for curing atrial fibrillation. Circulation 2000; 102: 2619-2628.
28. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation: A study in awake chronically instrumented goats. Circulation 1995; 92: 1954-1968.
29. Tanabe Y, Chinushi M, Taneda K, Fujita S, Kasai H, Yamaura M, et al. Recovery of the right atrial effective refractory period after cardioversion of chronic atrial fibrillation. Am J Cardiol 1999; 84: 1261-1264.
30. Sato T, Mitamura H, Kurita Y, Takeshita A, Shinagawa K, Miyoshi S, et al. Recovery of electrophysiological parameters after conversion of atrial fibrillation. Int J Cardiol 2001; 79: 183-189.
31. Aimé-Sempé C, Folliguet T, Rücker-Martin C, Krajewska M, Krajewska S, Heimburger M, et al. Myocardial cell death in fibrillating and dilated human right atria. J Am Coll Cardiol 1999; 34: 1577-1586.
32. Sanders P, Morton JB, Davidson NC, Spence SJ, Vohra JK, Sparks PB, et al. Electrical remodeling of the atria in congestive heart failure: Electrophysiological and electroanatomic mapping in humans. Circulation 2003; 108: 1461-1468.
33. Mary-Rabine L, Albert A, Pham TD, Hordof A, Fenoglio JJ Jr, Malm JR, et al. The relationship of human atrial cellular electrophysiology to clinical function and ultrastructure. Circ Res 1983; 52: 188-199.
34. Goette A, Staack T, Röcken C, Arndt M, Geller JC, Huth C, et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000; 35: 1669-1677.
35. Kanagaratnam P, Dupont E, Rothery S, Coppen S, Severs NJ, Peters NS. Human atrial conduction and arrhythmogenesis correlates with conformational exposure of specific epitopes on the connexin40 carboxyl tail. J Mol Cell Cardiol 2006; 40: 675-687.
36. Khan IA. Atrial stunning: Determinants and cellular mechanisms. Am Heart J 2003; 145: 787-794.
37. Berger M, Schweitzer P. Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: A retrospective analysis. Am J Cardiol 1998; 82: 1545-1547, A8.
38. Darbar D, Herron KJ, Ballew JD, Jahangir A, Gersh BJ, Shen WK, et al. Familial atrial fibrillation is a genetically heterogeneous disorder. J Am Coll Cardiol 2003; 41: 2185-2192.
39. Yamashita T, Murakawa Y, Hayami N, Fukui E, Kasaoka Y, Inoue M, et al. Short-term effects of rapid pacing on mRNA level of voltage-dependent K+ channels in rat atrium: Electrical remodeling in paroxysmal atrial tachycardia. Circulation 2000; 101: 2007-2014.
40. Coumel P. Neural aspects of paroxysmal atrial fibrillation. In: Falk RH, Podrid PJ, editors. Atrial fibrillation: Mechanisms and management. New York: Raven Press, 1992; 109-125.
41. Maisel WH. Autonomic modulation preceding the onset of atrial fibrillation. J Am Coll Cardiol 2003; 42: 1269-1270.
42. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 2004; 363: 2022-2031.
43. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlöf B, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45: 712-719.
44. Watanabe H, Ma M, Washizuka T, Komura S, Yoshida T, Hosaka Y, et al. Thyroid hormone regulates mRNA expression and currents of ion channels in rat atrium. Biochem Biophys Res Commun 2003; 308: 439-444.
45. Keer CR, Humphries KH, Talajic M, Klein GJ, Connolly SJ, Green M, et al. Progression of chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: Results from the Canadian Registry of Atrial Fibrillation. Am Heart J 2005; 149: 489-496.
46. Klein GJ, Bashore TM, Sellers TD, Pritchett EL, Smith WM, Gallagher JJ. Ventricular fibrillation in the Wolff-Parkinson-White syndrome. N Engl J Med 1979; 301: 1080-1085.
47. Yamashita T, Sekiguchi A, Iwasaki Y, Sagara K, Hatano S, Iinuma H, et al. Thrombomodulin and tissue factor pathway inhibitor in endocardium of rapidly paced rat atria. Circulation 2003; 108: 2450-2452.
48. Allessie MA, Lammers WJEP, Bonke FIM, Hollen J. Experimental evaluation of Moe's multiple wavelet hypothesis of atrial fibrillation. In: Zipes DP, Jalife J, editors. Cardiac electrophysiology and arrhythmias. Orlando, Grune & Stratton, 1985; 265-275.
49. Chen SA, Hsieh MH, Tai CT, Tsai CF, Prakash VS, Yu WC, et al. Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins: Electrophysiological characteristics, pharmacological responses, and effects of radiofrequency ablation. Circulation 1999; 100: 1879-1886.
50. Chen YJ, Chen SA, Chen YC, Yeh HI, Chan P, Chang MS, et al. Effects of rapid atrial pacing on the arrhythmogenic activity of single cardiomyocytes from pulmonary veins: Implication in initiation of atrial fibrillation. Circulation 2001; 104: 2849-2854.
51. Arora R, Verheule S, Scott L, Navarrete A, Katari V, Wilson E, et al. Arrhythmogenic substrate of the pulmonary veins assessed by high-resolution optical mapping. Circulation 2003; 107: 1816-1821.
52. Kumagai K, Khrestian C, Waldo AL. Simultaneous multisite mapping studies during induced atrial fibrillation in the sterile pericarditis model: Insights into the mechanism of its maintenance. Circulation 1997; 95: 511-521.
53. Allessie MA, Bonke FI, Schopman FJ. Circus movement in rabbit atrial muscle as a mechanism of tachycardia. III. The "leading circle" concept: A new model of circus movement in cardiac tissue without the involvement of an anatomical obstacle. Circ Res 1977; 41: 9-18.
54. Dillon SM, Allessie MA, Ursell PC, Wit AL. Influences of anisotropic tissue structure on reentrant circuits in the epicardial border zone of subacute canine infarcts. Circ Res 1988; 63: 182-206.
55. Pertsov AM, Davidenko JM, Salomonsz R, Baxter WT, Jalife J. Spiral waves of excitation underlie reentrant activity in isolated cardiac muscle. Circ Res 1993; 72: 631-650.
56. Rensma PL, Allessie MA, Lammers WJEP, Bonke FIM, Schalij MJ. Length of excitation wave and susceptibility to reentrant atrial arrhythmias in normal conscious dogs. Circ Res 1988; 62: 395-410.
57. Nattel S, Li D. Ionic remodeling in the heart: Pathophysiological significance and new therapeutic opportunities for atrial fibrillation. Circ Res 2000; 87: 440-447.
58. Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res 2002; 54: 230-246.
59. Li D, Shinagawa K, Pang L, Leung TK, Cardin S, Wang Z, et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 2001; 104: 2608-2614.
60. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, et al. Prevention of atrial fibrillation with angiotensinconverting enzyme inhibitors and angiotensin receptor blockers: A meta-analysis. J Am Coll Cardiol 2005; 45: 1832-1839.
61. Gallagher MM, Camm AJ. Classification of atrial fibrillation. Pacing Clin Electrophysiol 1997; 20: 1603-1605.
62. Israel CW, Grönefeld G, Ehrlich JR, Li YG, Hohnloser SH. Longterm risk of recurrent atrial fibrillation as documented by an implantable monitoring device: Implications for optimal patient care. J Am Coll Cardiol 2004; 43: 47-52.
63. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Circulation 2006; 114: e257-e354.
64. Humphries KH, Kerr CR, Connolly SJ, Klein G, Boone JA, Green M, et al. New-onset atrial fibrillation: Sex differences in presentation, treatment, and outcome. Circulation 2001; 103: 2365-2370.
65. Kato T, Yamashita T, Sagara K, Iinuma H, Fu LT. Progressive nature of paroxysmal atrial fibrillation: Observations from a 14- year follow-up study. Circ J 2004; 68: 568-572.
66. Sakamoto H, Okamoto E, Imataka K, Ieki K, Fujii J. Prediction of early development of chronic nonrheumatic atrial fibrillation. Jpn Heart J 1995; 36: 191-199.
67. Van Gelder IC, Crijns HJ, Tieleman RG, Brügemann J, De Kam PJ, Gosselink AT, et al. Chronic atrial fibrillation. Success of serial cardioversion therapy and safety of oral anticoagulation. Arch Intern Med 1996; 156: 2585-2592.
68. Camm AJ, Savelieva I, Baharati S, Lindsay BD, Nattel S, Shinagawa K, et al. Atrial tachycardia, flutter, and fibrillation. In; Electrophysiological disorders of the heart. Sakesena S, Camm AJ, editors. Philadelphia: Elsevier, Churchill Livingstone, 2005; 283-363.
69. J-RHYTHM Study.
70. McKenna WJ, Alfonso A. Arrhythmias in the cardiomyopathies and mitral valve prolapse. In: Zipes D, Rowlands D, editors. Progress in cardiology. Philadelphia: Lea & Febiger, 1988; 59-75.
71. Pollick C. Muscular subaortic stenosis: Hemodynamic and clinical improvement after disopyramide. N Engl J Med 1982; 307: 997-999.
72. Hamada M, Sigematsu Y, Ikeda S, Hara Y, Okayama H, Kodama K, et al. Class Ia antiarrhythmic drug cibenzoline: A new approach to the medical treatment of hypertrophic obstructive cardiomyopathy. Circulation 1997; 96: 1520-1524.
73. Nakazawa HK, Sakurai K, Hamada N, Momotani N, Ito K. Managenent of atrial fibrillation in the post-thyrotoxic state. Am J Med 1982; 72: 903-906.
74. Nakazawa H, Lythall DA, Noh J, Ishikawa N, Sugino K, Ito K, et al. Is there a place for the late cardioversion of atrial fibrillation? A long-term follow-up study of patients with post-thyrotoxic atrial fibrillation. Eur Heart J 2000; 21: 327-333.
75. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH et al. Prevalence, incidence and lifetime risk of atrial fibrillation: The Rotterdam study. Eur Heart J 2006; 27: 949-953.
76. Evans W, Swann P. Lone auricular fibrillation. Br Heart J 1954; 16: 189-194.
77. Brand FN, Abbot RD, Kannel WB, Wolf PA. Charcteristics and prognosis of lone atrial fibrillation: 30-year follow-up in the Framingham Study. JAMA 1985; 254: 3449-3453.
78. Kopecky SL, Gersh BJ, McGoon MD, Chu CP, Ilstrup DM, Chesebro JH, et al. Lone atrial fibrillation in elderly persons: A marker for cardiovascular risk. Arch Intern Med 1999; 159: 1118-1122.
79. Kopecky SL, Gersh BJ, McGoon MD, Whisnant JP, Holmes DR Jr, Ilstrup DM, et al. The natural history of lone atrial fibrillation. A population-based study over three decades. N Engl J Med 1987; 317: 669-674.
80. Odakura H, Ito M. Lone atrial fibrillation. In: Hayakawa H, Kasanuki H, editors. Atrial fibrillation, flutter, and tachycardia. Tokyo: Igaku-Shoin Ltd., 1999; 288-292 (in Japanese).
81. Frost L. Lone atrial fibrillation: Good, bad, or ugly? Circulation 2007; 115: 3040-3041.
82. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation: Pharmacological Intervention in Atrial Fibrillation (PIAF): A randomized trial. Lancet 2000; 356: 1789-1794.
83. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators: A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833.
84. Hagens VE, Ranchor AV, Van Sonderen ELP, Bosker HA, Kingma T, Van Gelder C. Quality of life in persistent atrial fibrillation in the RACE study. Circulation 2002; 106: II-634.
85. Carlsson J, Miketic S, Windeler J, Cuneo A, Haun S, Micus S, et al; STAF Investigators. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: The Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 2003; 41: 1690-1696.
86. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J 2006; 27: 1979-2030.
87. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255-1262.
88. Stroke Prevention in Atrial Fibrillation III randomised clinical trial investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348: 633-638.
89. Yamamoto K, Ikeda U, Furuhashi K, Irokawa M, Nakayama T, Shimada K. The coagulation system is activated in idiopathic cardiomyopathy. J Am Coll Cardiol 1995; 25: 1634-1640.
90. Nozawa T, Inoue H, Hirai T, Iwasa A, Okumura K, Lee JD, et al. D-dimer level influences thromboembolic events in patients with atrial fibrillation. Int J Cardiol 2006; 109: 59-65.
91. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: Results from the National Regisry of Atrial Fibrillation. JAMA 2001; 285: 2864-2870.
92. Inoue H, Nozawa T, Hirai T, Iwasa A, Okumura K, Lee JD, et al. Accumulation of risk factors increases risk of thromboembolic events in patients with nonvalvular atrial fibrillation. Circ J 2006; 70: 651-656.
93. Yamaguchi T for Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group: Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: A multicenter, prospective, randomized trial. Stroke 2000; 31: 817-821.
94. Yasaka M, Minematsu K, Yamaguchi T. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. Intern Med 2001; 40: 1183-1188.
95. Prystowsky EN, Benson DW Jr, Fuster V, Hart RG, Kay GN, Myerburg RJ, et al. Management of patients with atrial fibrillation: A statement for healthcare professionals. From the subcommittee on electrocardiography and electrophysiology, American Heart Association. Circulation 1996; 93: 1262-1277.
96. Hart RG, Halperin JL. Atrial fibrillation and thromboembolism: A decade of progress in stroke prevention. Ann Intern Med 1999; 131: 688-695.
97. Mancini GB, Goldberger AL. Cardioversion of atrial fibrillation: Consideration of embolization, anticoagulation, prophylactic pacemaker, and long-term success. Am Heart J 1982; 104: 617-621.
98. Klein AL, Grimm RA, Murray RD, Apperson-Hansen C, Asinger RW, Black IW, et al; Assessment of Cardioversion Using Transesophageal Echocardiography Investigators: Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 2001; 344: 1411-1420.
99. Mehta D, Baruch L. Thromboembolism following cardioversion of "common" atrial flutter: Risk factors and limitations of transesophageal echocardiography. Chest 1996; 110: 1001-1003.
100. Irani WN, Grayburn PA, Afridi I. Prevalence of thrombus, spontaneous echo contrast, and atrial stunning in patients undergoing cardioversion of atrial flutter: A prospective study using transesophageal echocardiography. Circulation 1997; 95: 962-966.
101. Wahl MJ. Dental surgery in anticoagulated patients. Arch Intern Med 1998; 158: 1610-1616.
102. Yasaka M, Naritomi H, Minematsu K. Ischemic stroke associated with brief cessation of warfarin. Thromb Res 2006; 118: 290-293.
103. Evans IL, Sayers MS, Gibbons AJ, Price G, Snooks H, Sugar AW. Can warfarin be continued during dental extraction? Result of a randomized controlled trial. Br J Oral Maxillofac Surg 2002; 40: 248-252.
104. Morimoto Y, Niwa H, Yoneda T, Kimura K, Yasaka M, Minematsu K. Hemostatic management of tooth extraction in patients undergoing antithrombotic therapy. J Jpn Stomatol Soc 2004; 53: 74-80 (in Japanese).
105. Makiura N, Yasaka M, Minematsu K. Management of hemorrhagic complications at dental extraction in patients treated with warfarin. Jpn J Stroke 2005; 27: 424-427 (in Japanese).
106. Morimoto Y, Niwa H, Yoneda T, Shimabukuro Y, Kitamura M, Murakami S, et al. Hemostatic management of dental treatments in the patients undergoing antithrombotic therapy. Journal of the Japanese Association for Dental Science: JJDS 2006; 25: 93-98 (in Japanese).
107. Ardekian L, Gaspar R, Peled M, Brener B, Laufer D. Does lowdose aspirin therapy complicate oral surgical procedures? J Am Dent Assoc 2000; 131: 331-335.
108. Katz J, Feldman MA, Bass EB, Lubomski LH, Tielsch JM, Petty BG, et al; Study of Medical Testing for Cataract Surgery Team. Risks and benefits of anticoagulant and antiplatelet medication use before cataract surgery. Ophthalmology 2003; 110: 1784-1788.
109. Yasaka M, Okada Y, Enaida H, Takahashi S, Yamaguchi T. A questionnaire survey on antithrombotic therapy during cataract surgery. Jpn Med J 2008; 4382: 74-75 (in Japanese).
110. Ogoshi K, Kaneko E, Tada M, Mine T, Yoshino J, Yahagi N, et al. The management of anticoagulation and antiplatelet therapy for endoscopic procedures. Gastroenterol Endosc 2005; 47: 2691-2695 (in Japanese).
111. Guidelines for the Diagnosis and Treatment of Cardiovascular Diseases (2002-2003 JCS Joint Working Groups Report). Guidelines for management of anticoagulant and antiplatelet therapy in cardiovascular disease. Circ J 2004; 68(Suppl IV): 1153-1219 (in Japanese).
112. Yasaka M, Minematsu K, Naritomi H, Sakata T, Yamaguchi T. Predisposing factors for enlargement of intracerebral hemorrhage in patients treated with warfarin. Thromb Haemost 2003; 89: 278-283.
113. Yasaka M, Sakata T, Minematsu K, Naritomi H. Correction of INR by prothrombin complex concentrate and vitamin K in patients with warfarin related hemorrhagic complication. Thromb Res 2002; 108: 25-30.
114. Yasaka M, Sakata T, Naritomi H, Minematsu K. Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation. Thromb Res 2005; 115: 455-459.
115. Aguilar MI, Hart RG, Kase CS, Freeman WD, Hoeben BJ, García RC, et al. Treatment of warfarin-associated intracerebral hemorrhage: Literature review and expert opinion. Mayo Clin Proc 2007; 82: 82-92.
116. Kenet G, Walden R, Eldad A, Martinowitz U. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 1999; 354: 1879.
117. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, et al; Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005; 352: 777-785.
118. Mayer SA, Brun NC, Broderick J, Davis S, Diringer MN, Skolnick BE, et al; Europe/AustralAsia NovoSeven ICH Trial Investigators. Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage. Stroke 2005; 36: 74-79.
119. Aosaki M, Iwade K, Echizen H. V-1: Use during pregnancy (contraindications). In: Aosaki M, Iwade K, Echizen H, editors. Warfarin- Proper use information version 3. Tokyo: Eisai Co., Ltd., 2007; 107-109 (in Japanese).
120. Uetsuka Y, Higashidate N, Aosaki M, Matsumura K, Fukui T, Iwade K, et al. Fifteen-year experience with 24 pregnancies associated with prosthetic valve replacements. J Cardiol 1990; 20: 929-935 (in Japanese).
121. Halperin JL; Executive Steering Committee, SPORTIF III and V Study Investigators. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J 2003; 146: 431-438.
122. Rawles JM. What is meant by a "controlled" ventricular rate in atrial fibrillation? Br Heart J 1990; 63: 157-161.
123. Galve E, Rius T, Ballester R, Artaza MA, Arnau JM, García- Dorado D, et al. Intravenous amiodarone in treatment ofrecentonset atrial fibrillation: Results of a randomized, controlled study. J Am Coll Cardiol 1996; 27: 1079-1082.
124. Lundström T, Rydén L. Ventricular rate control and exercise performance in chronic atrial fibrillation: Effects of diltiazem and verapamil. J Am Coll Cardiol 1990; 16: 86-90.
125. The Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group. Intravenous digoxin in acute atrial fibrillation: Results of a randomized, placebo-controlled multicentre trial in 239 patients. Eur Heart J 1997; 18: 649-654.
126. Enjoji Y, Sugi K, Kasao M, Ikeda T, Noro M, Sakata T, et al. The usefulness of aprindine for the defibrillation of paroxysmal atrial fibrillation resistant to DC shock. Kokyu To Junkan 1996; 44: 1287-1291 (in Japanese).
127. Suttorp MJ, Kingma JH, Jessurun ER, Lie-A-Huen L, van Hemel NM, Lie KI. The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. J Am Coll Cardiol 1990; 16: 1722-1727.
128. Capucci A, Boriani G, Rubino I, Della Casa S, Sanguinetti M, Magnani B. A controlled study on oral propafenone versus digoxin plus quinidine in converting resent onset atrial fibrillation to sinus rhythm. Int J Cardiol 1994; 43: 305-313.
129. Donovan KD, Power BM, Hockings BE, Dobb GJ, Lee KY. Intravenous flecainide versus amiodarone for recent-onset atrial fibrillation. Am J Cardiol 1995; 75: 693-697.
130. Halinen MO, Huttunen M, Paakkinen S, Tarssanen L. Comparison of sotalol with digoxin-quinidine for conversion of acute atrial fibrillation to sinus rhythm (the Sotalol-DigoxinQuinidine Trial). Am J Cardiol 1995; 76: 495-498.
131. Azpitarte J, Alvarez M, Baún O, García R, Moreno E, Martín F, et al. Value of single oral loading dose of propafenone in converting recent-onset atrial fibrillation. Results of a randomized, double- blind, controlled study. Eur Heart J 1997; 18: 1649-1654.
132. Okishige K, Fukunami M, Kumagai K, Atarashi H, Inoue H; Pilsicainide Suppression Trial for Persistent Atrial Fibrillation II Investigators. Pharmacological conversion of persistent atrial fibrillation into sinus rhythm with oral pilsicainide: Pilsicainide suppression trial for persistent atrial fibrillation II. Circ J 2006; 70: 657-661.
133. Atarashi H, Inoue H, Hiejima K, Hayakawa H; PSTAF Investigators. Conversion of recent-onset atrial fibrillation by a single oral dose of pilsicainide (Pilsicainide Suppression Trial on atrial fibrillation). Am J Cardiol 1996; 78: 694-697.
134. Guidelines for the Diagnosis and Treatment of Cardiovascular Diseases (2002-2003 JCS Joint Working Groups Report). Guidelines for pharmacologic treatment of arrhythmias. Circ J 2004; 68(Suppl IV): 981-1053 (in Japanese).
135. The Antiarrhythmic Drugs Guideline Committee of the Japanese Society of Electrocardiology. Prospects for preparation of the guidelines for the use of antiarrhythmic drugs according to the Sicilian Gambit. Electrocardiography 1997; 17: 191-197 (in Japanese).
136. Kochiadakis GE, Igoumenidis NE, Solomou MC, Kaleboubas MD, Chlouverakis GI, Vardas PE. Efficacy of amiodarone for the termination of persistent atrial fibrillation. Am J Cardiol 1999; 83: 58-61.
137. Perelman MS, McKenna WJ, Rowland E, Krikler DM. A comparison of bepridil with amiodarone in the treatment of established atrial fibrillation. Br Heart J 1987; 58: 339-344.
138. Nakazato Y, Yasuda M, Sasaki A, Iida Y, Kawano Y, Nakazato K, et al. Conversion and maintenance of sinus rhythm by bepridil in patients with persistent atrial fibrillation. Circ J 2005; 69: 44-48.
139. Fujiki A, Tsuneda T, Sugao M, Mizumaki K, Inoue H. Usefulness and safety of bepridil in converting persistent atrial fibrillation to sinus rhythm. Am J Cardiol 2003; 92: 472-475.
140. Matsumoto K, Sumita S, Ishikawa T, Matsushita K, Kobayashi T, Ohkusu Y, et al. Brugada syndrome associated with ventricular fibrillation induced by administration of pilsicainide: A case report. J Cardiol 2003; 42: 227-234 (in Japanese).
141. Reisinger J, Gatterer E, Heinze H, Wiesinger K, Zeindlhofer E, Gattermeier M, et al. Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation. Am J Cardiol 1998; 81: 1450-1454.
142. Singh BN, Singh SN, Reda DJ, Tang XC, Lopez B, Harris CL, et al; Sotalol Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T) Investigators. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005; 352: 1861-1872.
143. Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, et al. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med 2000; 342: 913-920.
144. AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: An AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol 2003; 42: 20-29.
145. Pedersen OD, Bagger H, Køber L, Trop-Pedersen C; on behalf of the TRACE Study Group. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999; 100: 376-380.
146. Vermes E, Tardif JC, Bourassa MG, Racine N, Levesque S, White M, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: Insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003; 107: 2926-2931.
147. Maggioni AP, Latini R, Carson PE, Singh SN, Barlera S, Glazer R, et al; Val-HeFT Investigators. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005; 149: 548-557.
148. Kühlkamp V, Schirdewan A, Stangl K, Homberg M, Ploch M, Beck OA. Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: A randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 2000; 36: 139-146.
149. Watanabe E, Arakawa T, Uchiyama T, Kani A, Kato K, Kodama I, et al. Prevention of paroxysmal atrial fibrillation by class I antiarrhythmic drugs based on diurnal event variation. Electrocardiology 2003; 23: 45-52 (in Japanese).
150. Alboni P, Botto GL, Baldi N, Luzi M, Russo V, Gianfranchi L, et al. Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. N Engl J Med 2004; 351: 2384-2391.
151. Jaïs P, Peng JT, Shah DC, Garrigue S, Hocini M, Yamane T, et al. Left ventricular diastolic dysfunction in patients with so-called line atrial fibrillation. J Cardiovasc Electrophysiol 2000; 11: 623-625.
152. Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa K, Saku K. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 2003; 41: 2197-2204.
153. Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, et al; CHARM Investigators. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006; 152: 86-92.
154. Madrid AH, Bueno MG, Rebollo JM, Marín I, Peña G, Bernal E, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: A prospective and randomized study. Circulation 2002; 106: 331-336.
155. Hirayama Y, Atarashi H, Kobayashi Y, Horie T, Iwasaki Y, Maruyama M, et al. Angiotensin-converting enzyme inhibitor therapy inhibits the progression from paroxysmal atrial fibrillation to chronic atrial fibrillation. Circ J 2005; 69: 671-676.
156. Yamashita T, Ogawa S, Aizawa Y, Atarashi H, Inoue H, Ohe T, et al; on behave of the J-RHYTHM II Investigators. Randomized study of angiotensin II type 1 receptor blocker vs dihydropiridine calcium antagonist for the treatment of paroxysmal atrial fibrillation in patients with hypertension: The J-RHYTHM II study design for the investigation of upstream therapy for atrial fibrillation. Circ J 2006; 70: 1318-1321.
157. Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, et al. C-reactive protein elevation in patients with atrial arrhythmias: Inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001; 104: 2886-2891.
158. Kumagai K, Nakashima H, Saku K. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res 2004; 62: 105-111.
159. Ouyang F, Bänsch D, Ernst S, Schaumann A, Hachiya H, Chen M, et al. Complete isolation of left atrium surrounding the pulmonary veins: New insights from the double-Lasso technique in paroxysmal atrial fibrillation. Circulation 2004; 110: 2090-2096.
160. Oral H, Pappone C, Chugh A, Good E, Bogun F, Pelosi F Jr, et al. Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med 2006; 354: 934-941.
161. Nademanee K, McKenzie J, Kosar E, Schwab M, Sunsaneewitayakul B, Vasavakul T, et al. A new approach for catheter ablation of atrial fibrillation: Mapping of the electrophysiologic substrate. J Am Coll Cardiol 2004; 43: 2044-2053.
162. Scanavacca M, Pisani CF, Hachul D, Lara S, Hardy C, Darrieux F, et al. Selective atrial vagal denervation guided by evoked vagal reflex to treat patients with paroxysmal atrial fibrillation. Circulation 2006; 114: 876-885.
163. Hocini M, Jaïs P, Sanders P, Takahashi Y, Rotter M, Rostock T, et al. Techniques, evaluation, and consequences of linear block at the left atrial roof in paroxysmal atrial fibrillation: A prospective randomized study. Circulation 2005; 112: 3688-3696.
164. Oral H, Knight BP, Ozaydin M, Chugh A, Lai SW, Scharf C, et al. Segmental ostial ablation to isolate the pulmonary veins62. during atrial fibrillation: Feasibility and mechanistic insights. Circulation 2002; 106: 1256-12
165. Oral H, Knight BP, Tada H, Ozaydin M, Chugh A, Hassan S, et al. Pulmonary vein isolation for paroxysmal and persistent atrial fibrillation. Circulation 2002; 105: 1077-1081.
166. Wazni OM, Marrouche NF, Martin DO, Verma A, Bhargava M, Saliba W, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: A randomized trial. JAMA 2005; 293: 2634-2640.
167. Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, et al. Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation 2005; 111: 1100-1105.
168. Oral H, Chugh A, Good E, Igic P, Elmouchi D, Tschopp DR, et al. Randomized comparison of encircling and nonencircling left atrial ablation for chronic atrial fibrillation. Heart Rhythm 2005; 2: 1165-1172.
169. Oral H, Chugh A, Ozaydin M, Good E, Fortino J, Sankaran S, et al. Risk of thromboembolic events after percutaneous left atrial radiofrequency ablation of atrial fibrillation. Circulation 2006; 114: 759-765.
170. Di Biase L, Fahmy TS, Wazni OM, Bai R, Patel D, Lakkireddy D, et al. Pulmonary vein total occlusion following catheter ablation for atrial fibrillation: Clinical implications after long-term followup. J Am Coll Cardiol 2006; 48: 2493-2499.
171. Cummings JE, Schweikert RA, Saliba WI, Burkhardt JD, Kilikaslan F, Saad E, et al. Brief communication: Atrialesophageal fistulas after radiofrequency ablation. Ann Intern Med 2006; 144: 572-574.
172. Sacher F, Monahan KH, Thomas SP, Davidson N, Adragao P, Sanders P, et al. Phrenic nerve injury after atrial fibrillation catheter ablation: Characterization and outcome in a multicenter study. J Am Coll Cardiol 2006; 47: 2498-2503.
173. Brignole M, Menozzi C, Gianfranchi L, Musso G, Mureddu R, Bottoni N, et al. Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation: A randomized, controlled study. Circulation 1998; 98: 953-960.
174. Wood MA, Brown-Mahoney C, Kay GN, Ellenbogen KA. Clinical outcomes after ablation and pacing therapy for atrial fibrillation: A meta-analysis. Circulation 2000; 101: 1138-1144.